StockStory advises avoiding Thermo Fisher, Envista, and Inspire Medical Systems
StockStory has identified three healthcare stocks that investors should avoid due to regulatory risks and fundamental performance issues. The healthcare sector has gained 31.5% over the past six months, outperforming the S&P 500 by 24.7 percentage points, yet the firm argues that specific companies within the group warrant caution. The report highlights Thermo Fisher Scientific, Envista Holdings, and Inspire Medical Systems as names to steer clear of.
StockStory has identified three healthcare stocks that investors should avoid due to regulatory risks and fundamental performance issues. The healthcare sector has gained 31.5% over the past six months, outperforming the S&P 500 by 24.7 percentage points, yet the firm argues that specific companies within the group warrant caution. The report highlights Thermo Fisher Scientific, Envista Holdings, and Inspire Medical Systems as names to steer clear of.
Thermo Fisher Scientific (NYSE:TMO) operates with a market capitalization of $249.1 billion. The company employs over 14,000 sales personnel and manages a portfolio spanning more than 2,500 technology manufacturers. It supplies lab tools, materials, and digital solutions to clients in the pharma, biotech, academic, and medical fields globally. StockStory notes that Thermo Fisher's large scale limits its growth potential compared to smaller competitors. Annual revenue increases have averaged 3.9% over the last five years, a figure described as below average. The report points to an absence of organic revenue growth over the past two years, suggesting the company may rely on acquisitions for expansion. Earnings per share have remained flat over the last five years, lagging peer performance. At $676.39 per share, Thermo Fisher trades at a 25.1x forward P/E ratio.
Envista Holdings (NYSE:NVST) has a market capitalization of $3.79 billion. The global dental products company unites more than 30 brands, including Nobel Biocare, Ormco, and DEXIS, providing equipment, consumables, and specialized technologies for dental professionals. StockStory cites annual revenue growth of 3.4% over the last five years as slower than its healthcare peers. Over the same period, earnings per share fell by 7% annually, indicating that incremental sales were less profitable. The report states that the push for growth has led to negative returns on capital, signaling value destruction and suggesting that historical profit centers are aging. Envista's stock price of $23.61 implies a valuation ratio of 15.3x forward P/E.
Inspire Medical Systems (NYSE:INSP) holds a market capitalization of $2.06 billion. The company develops and sells an implantable neurostimulation device designed to treat obstructive sleep apnea by stimulating nerves to keep airways open during sleep. This device offers an alternative for patients who struggle with traditional CPAP machines. StockStory notes that Inspire's revenue base of $898.7 million is smaller than that of industry leaders, meaning it has not achieved comparable economies of scale. The firm cites a forecasted revenue decline of 3.4% for the upcoming 12 months, implying a drop in demand. Inspire Medical Systems is trading at $71.20 per share, representing a 53.4x forward P/E valuation.